Is DSIP FDA approved? The honest regulatory answer

Last updated 2026-07-26

Is DSIP FDA approved for sleep or any other use?

No. There is no FDA-approved drug product that contains DSIP, and no FDA indication exists for insomnia, stress, or anything else tied to this peptide. You can check this yourself: the FDA's Orange Book, which lists every approved drug product with therapeutic equivalence ratings, has no entry for DSIP under any name (delta sleep-inducing peptide, DSIP, or its chemical designation) ^[1]. That absence matters more than it might seem. Drugs don't get FDA approval by being studied a few times in the 1970s and 80s. They get approval through a New Drug Application (NDA) that includes controlled human trials, manufacturing data, and safety monitoring, reviewed under the Federal Food, Drug, and Cosmetic Act ^[2]. DSIP has never had an NDA filed, let alone approved. No sponsor has taken it through Phase 3 trials for sleep in the United States. So when a product page says "DSIP" and shows a vial, that's not an FDA-approved medication. It's either a research chemical sold for laboratory use, or a compounded preparation, and neither category involves FDA premarket approval of safety and effectiveness.

What exactly is DSIP, and where did the name come from?

DSIP is a nonapeptide (a chain of nine amino acids, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the blood of rabbits during sleep-deprivation experiments in the 1970s ^[3]. Researchers Schoenenberger and Monnier described it after perfusing blood from sleep-deprived rabbits and finding a substance that seemed to induce delta-wave (slow-wave) sleep patterns in other rabbits. The name stuck, but it's arguably done the peptide a disservice. "Delta sleep-inducing peptide" sounds like a settled mechanism. In reality, the peptide's actual role in sleep physiology was never nailed down, and later researchers found DSIP-like immunoreactivity in tissues that have nothing to do with sleep. Some papers proposed it acts more like a stress-response modulator or a general homeostatic peptide than a dedicated sleep hormone ^[3]. Worth saying plainly: most of what's cited about DSIP comes from animal studies, and a good chunk of the human work is small, uncontrolled, or from an era before modern trial design standards. That's not a knock on the researchers of the time, it's just the honest state of the record. For the fuller research history, see the DSIP overview page.

Has DSIP been tested in human clinical trials at all?

Yes, but the human trials are old, small, and mixed in outcome. This is not a peptide with a modern Phase 2 or Phase 3 program behind it. One of the more cited human studies is a 1990s trial in patients with psychophysiological insomnia. Schneider-Helmert (1985) reported that DSIP administered to a small group of chronic insomnia patients produced some improvement in subjective sleep quality, but the study was limited in size and didn't establish a consistent effect on objective sleep architecture across all participants ^[4]. Other trials from the same period looked at DSIP in opioid withdrawal and in stress-related conditions, again in small cohorts. A frequently referenced review in Peptides (Kastin and colleagues) summarized the DSIP literature through the late 1990s and noted that despite decades of research, "the physiological function of DSIP remains unclear" and that clinical effects reported in early trials were not reliably reproduced ^[3]. That's about as candid an assessment as you'll find in the primary literature. No trial registered on ClinicalTrials.gov currently lists DSIP as an active investigational drug for insomnia in the United States. Searching the registry for "delta sleep-inducing peptide" turns up essentially nothing in the modern era. That absence of current trials is itself informative: a compound genuinely on a path toward approval would have an active IND (Investigational New Drug application) and registered studies. DSIP doesn't.

Is DSIP legal to buy in the US?

Legality and FDA approval are two different questions, and this is where people get confused. DSIP is not a scheduled controlled substance under the Controlled Substances Act, so possessing the raw peptide isn't a DEA scheduling issue ^[5]. But that doesn't mean it's approved for human use or that selling it as a treatment is legal. Most DSIP sold in the US is labeled "research use only," meaning the seller is telling the FDA and the buyer that it's intended for laboratory research on non-human subjects, not for people to inject. Marketing an RUO product for human sleep or stress treatment would put a seller outside that carve-out and into unapproved-drug territory under the FD&C Act ^[2]. The other legal channel is compounding. DSIP is not on the FDA's 503A bulk drug substances list nor the 503B outsourcing facility bulks list, meaning compounding pharmacies do not have a categorical green light to compound it the way they might with an FDA-recognized bulk substance ^[6]. Some compounders still work with peptides like this under individual prescriber relationships, but the regulatory footing is much shakier than for approved bulk substances, and enforcement posture has tightened peptide by peptide over the past few years. If you're going to pursue DSIP despite the thin evidence, source matters enormously here. A provider-reviewed process, where a licensed prescriber evaluates you and a legitimate pharmacy fulfills the prescription, is a materially different risk profile than an anonymous vial from an unregulated "research chemical" storefront. DSIP Peptide's site keeps the sourcing conversation anchored to that provider-reviewed model rather than direct-to-consumer vial sales; see buy dsip for how that path is described.

Why isn't there an FDA-approved DSIP drug if it's been studied since the 1970s?

Money and mechanism, mostly. Getting a drug through FDA approval costs enormous sums and takes years of trial infrastructure most academic peptide research never had backing for. Tufts Center for the Study of Drug Development has estimated the full cost of bringing a new drug to market, including failures, at over $2 billion in earlier analyses, and newer figures push higher still ^[7]. Nobody has ever funded that kind of program for DSIP. There's also a mechanism problem. To get an NDA approved, a sponsor needs "substantial evidence" of effectiveness from adequate and well-controlled trials, per FDA's own standard under 21 CFR 314.126 ^[8]. DSIP's early positive results didn't reliably replicate, and the peptide's actual receptor and mechanism were never clearly established the way melatonin receptors or GABA-A modulation are for approved sleep drugs. Without a clean mechanism and consistent trial data, no sponsor has had a package worth submitting. Compare that to an approved insomnia drug like suvorexant (Belsomra), which went through FDA's standard NDA pathway with Phase 3 trials enrolling thousands of patients before its 2014 approval . That's the bar. DSIP has never been near it.

Is DSIP the same thing as an FDA-approved sleep aid?

No, and the comparison is worth making explicit because people sometimes assume any "peptide for sleep" sits in the same regulatory category as prescription sleep medications. It doesn't. | | DSIP | Suvorexant (Belsomra) | Zolpidem (Ambien) |

What does the actual DSIP research say it might do, if anything?

The most defensible summary is this: early animal work suggested DSIP could promote delta-wave (slow-wave) sleep patterns and had some influence on the hypothalamic-pituitary-adrenal stress axis, and a handful of small human trials in the 1980s-90s reported subjective sleep or withdrawal-symptom improvements, but none of this rises to the level of established, reproducible human efficacy data ^{[3] [3] [4]}. A lot of the stress-axis interest comes from animal studies looking at ACTH and cortisol modulation, not human sleep trials. It's a common problem in how this peptide gets talked about online: an animal finding on stress hormones gets casually presented as if it means "DSIP reduces stress in people," when the actual paper never tested that in humans at all. Real coverage of the mechanism and study limitations lives on the dsip evidence page, and it's worth reading before deciding anything. If you're trying to figure out whether DSIP "works," the honest answer is: nobody has good modern human data to say yes or no with confidence. The 1980s trials are too small and too methodologically dated to settle the question either way.

Can a doctor legally prescribe DSIP?

A licensed prescriber can write for DSIP through legitimate compounding channels in some cases, similar to how prescribers use other non-FDA-approved peptides under individualized patient care, but it's not a standard prescription the way an FDA-approved drug is, and it won't be filled at a normal retail pharmacy or covered by insurance. This works, when it works, through 503A compounding pharmacies operating under state board of pharmacy oversight and a valid patient-specific prescription, not through FDA drug approval ^[6]. The distinction matters for accountability: compounded products don't go through FDA's premarket review of safety and effectiveness, so quality control depends heavily on which pharmacy is doing the compounding and how it's regulated at the state level. This is also exactly where sourcing quality separates a reasonable approach from a risky one. A provider-reviewed model, where a clinician actually assesses your history before anything is prescribed, and a named, accountable pharmacy does the compounding, is the responsible version of this pathway. Anonymous vials shipped from research-chemical sites with no clinician involved are a different and riskier thing entirely, regardless of what the label claims about purity.

What are the risks of using an FDA-unapproved peptide like DSIP?

The core risk is that nobody has systematically documented what happens with real-world human dosing, because no FDA-scale safety program has ever monitored it. Adverse event reporting, manufacturing standards, and dose-finding data that exist for approved drugs simply don't exist here at the same depth. Reported side effects in the sparse literature and in real-world use include injection site irritation, headache, dizziness, and vivid dreaming, but there's no large safety database to say how common these actually are or what happens with long-term use ^[4]. Full side effect detail is covered on dsip peptide side effects, and anyone considering this should read it before, not after, starting. There's also a quality-control risk specific to unregulated sourcing: peptides sold as "research use only" from unverified suppliers have no guarantee of purity, correct sequence, or accurate concentration. A 2022 analysis published in JAMA Dermatology of unapproved compounded and research peptides (in a related product category) found substantial batch-to-batch inconsistency, a pattern that shows up across the unregulated peptide market generally, not specific to DSIP but relevant to how the whole category gets sourced .

How does DSIP's regulatory status compare to other research peptides?

DSIP sits in roughly the same regulatory bucket as most "research peptides" marketed for sleep, recovery, or anti-aging: no FDA approval, no NDA, sold either as RUO material or through discretionary compounding. It's not uniquely unapproved, it's just one entry in a large category. A few peptides in adjacent spaces have made it further. Tesamorelin (Egrifta) is FDA-approved, but specifically for HIV-associated lipodystrophy, not sleep or general wellness, and it went through a full NDA process . That contrast is useful: it shows the pathway exists and has been walked successfully by other peptides, DSIP just never had a sponsor take it there. For readers weighing DSIP against other options, the honest framing is that "unapproved" doesn't automatically mean "unsafe" or "useless," but it does mean the burden of evidence and quality control falls entirely on you and whoever is prescribing or compounding it, not on FDA premarket review.

What should you actually look for before considering DSIP?

Given the thin evidence and lack of approval, the practical checklist looks different than it would for an approved drug. First, ask whether a licensed prescriber is actually evaluating you, more than processing an order form. Second, ask whether the pharmacy fulfilling it is a real, state-licensed compounding pharmacy, not an unnamed overseas lab shipping vials labeled research use only. Third, get real about dosing. Because there's no FDA-approved label, there's no FDA-reviewed dosing information either; anything you see is extrapolated from small old trials or from compounding pharmacy protocols. The dsip dosage and dsip dosage calculator pages walk through how researchers and prescribers have approached this in absence of an approved label, and dsip peptide injection covers administration technique if you're working with a prescriber who has decided it's appropriate for you. Finally, set expectations correctly. This is not an FDA-approved insomnia treatment with a large trial base behind it. It's a decades-old research peptide with a suggestive but unresolved animal and small-human literature. That's a very different thing to sign up for than a prescription sleep aid, and going in with clear eyes about that gap matters more than any dosing detail.

Frequently asked questions

Is DSIP approved by the FDA for insomnia?

No. There is no FDA-approved drug product containing DSIP for insomnia or any other condition. It doesn't appear in the FDA's Orange Book of approved drugs, and no New Drug Application has ever been approved for it in the United States.

Is DSIP a controlled substance?

No, DSIP is not scheduled under the Controlled Substances Act. That means simple possession isn't a DEA scheduling issue, but it's separate from FDA approval. It's still not an approved drug, and selling it labeled for human treatment use outside proper prescribing and compounding channels can run afoul of the FD&C Act.

Can I buy DSIP legally in the US?

You can obtain it through research-use-only channels (not for human use) or through compounding pharmacies acting on a valid prescriber's order, though DSIP isn't on FDA's 503A bulk substances list, which limits the legal footing compared to recognized bulk drugs. A provider-reviewed, pharmacy-fulfilled route is the more accountable option.

Has DSIP ever been tested in human clinical trials?

Yes, but only in small, older studies, mostly from the 1980s and 90s, looking at insomnia and stress-related conditions. These trials had limited sample sizes and mixed results, and none led to a modern FDA submission. No active trials are currently registered for DSIP in insomnia on ClinicalTrials.gov.

What does DSIP actually stand for?

DSIP stands for delta sleep-inducing peptide, a name given after it was isolated from sleep-deprived rabbit blood in the 1970s by Schoenenberger and Monnier. Despite the name, its actual role in human sleep physiology was never firmly established in the decades of research that followed.

Why hasn't a pharmaceutical company pursued FDA approval for DSIP?

Likely a mix of inconsistent early trial results, an unclear mechanism of action, and the enormous cost of modern drug development, estimated at over $2 billion per approved drug in Tufts Center analyses. Without a clean, replicable efficacy signal, there's no commercial case to fund the Phase 2/3 program required.

Is DSIP the same as melatonin or prescription sleep aids?

No. Melatonin is an FDA-regulated dietary supplement ingredient with a well-characterized receptor mechanism, and drugs like suvorexant (Belsomra) or zolpidem (Ambien) are FDA-approved through full NDA programs with large Phase 3 trials. DSIP has none of that regulatory or trial history behind it.

What are the side effects of DSIP?

Reported effects in the sparse literature include injection site irritation, headache, dizziness, and vivid dreaming, but there's no large safety database because DSIP has never gone through FDA-scale trials or postmarket monitoring. See the dedicated side effects page for fuller detail before considering use.

Can a doctor prescribe DSIP even though it's not FDA approved?

In some cases yes, through legitimate compounding pharmacy channels and an individualized prescription, similar to how other non-approved peptides get used in clinical practice. It won't be filled at a standard retail pharmacy or covered by insurance, and quality depends heavily on which compounding pharmacy is involved.

Is DSIP sold as research chemical the same quality as a prescription?

No. Research-use-only DSIP has no FDA oversight of purity, dose accuracy, or manufacturing standards, and quality varies a lot between suppliers. A provider-reviewed process with a named, licensed compounding pharmacy gives real accountability that anonymous vial sellers don't.

Does DSIP show up on the FDA's list of approved bulk compounding substances?

No. DSIP is not currently on the FDA's 503A bulk drug substances list or the 503B outsourcing facility list, which means compounding pharmacies don't have a blanket regulatory green light to compound it, unlike substances explicitly recognized on those lists.

Is there any FDA-approved peptide similar to DSIP for sleep or stress?

Not for sleep specifically. Some peptides in adjacent categories, like tesamorelin (Egrifta) for HIV-associated lipodystrophy, have achieved FDA approval through full NDA programs, showing the pathway is possible, but no sponsor has taken DSIP through that process for any indication.

Sources

1. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: No FDA-approved drug product contains DSIP under any name
2. FDA, Federal Food, Drug, and Cosmetic Act (New Drug requirements): New drugs require FDA approval via NDA before marketing for human treatment use
3. Schoenenberger & Monnier, original DSIP isolation research summarized in Peptides: DSIP was first isolated from sleep-deprived rabbit blood in the 1970s
4. Schneider-Helmert D, 'DSIP in the treatment of severe therapy-resistant insomnia,' Neuropsychobiology: Small human trial of DSIP in chronic insomnia patients reported limited and inconsistent effects on sleep
5. DEA, Controlled Substances Act schedules: DSIP is not listed as a scheduled controlled substance
6. FDA, 21 CFR 314.126 (Adequate and well-controlled studies): FDA requires substantial evidence from adequate and well-controlled trials for drug approval
7. FDA, Belsomra (suvorexant) approval and prescribing information: Suvorexant was FDA approved in 2014 following Phase 3 trials with thousands of patients
8. JAMA Dermatology, analysis of compounded/unapproved peptide product quality: Unregulated compounded and research peptide products show batch-to-batch quality inconsistency